Examination about the usefulness and life prognosis factor of the beta blocker in sepsis

• Project/Area Number: 15K10965
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Emergency medicine
• Research Institution: Asahikawa Medical College
• Principal Investigator: Motoi Okada 旭川医科大学, 医学部, 准教授 (80431427)
• Co-Investigator(Kenkyū-buntansha): 藤田 智 旭川医科大学, 医学部, 教授 (10173428) ; 西浦 猛 旭川医科大学, 医学部, 客員助教 (90567041) ; 柏木 友太 旭川医科大学, 医学部, 助教 (70648336)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: 心不全 / β遮断薬 / 敗血症 / テロメア / 敗血症性心不全 / カルベジロール / CLP / 敗血症性心筋症

Outline of Final Research Achievements

we confirmed the effectiveness of the carvedilol for anti-apoptosis and maintain of the telomeric length with the oxidized cultured cardiomyoblast cell. By the experiment using the mouse CLP model, a suppressant effect and a life prognosis improvement effect were shown a cardiac dysfunction in the carvedilol group. We recognized an expression drop of p53 with the myocardium, expression increase of pgc-1a, tert in the carvedilol group, and mitochondria function improved it more. Even telomeric Q-FISH analysis in a white blood cell accepted extension of the telomere length.
In treatment of the heart failure sepsis-related than the above, carvedilol can expect the restraint of the myocardium mitochondria dysfunction, cardioprotection action heart, a life prognosis improvement effect through the improvement of the energy metabolism.

Research Products

• [Presentation] Usefulness of the patch type beta blocker for the rate control of sepsis (2017)
  • Author(s): Motoi Okada
  • Organizer: 日本集中治療学会
• [Presentation] 侵襲反応を制御する～基礎研究（臨床への架け橋）」敗血症性心筋症でのβ3受容体の役割 (2017)
  • Author(s): 岡田 基
  • Organizer: 日本救急医学会
• [Presentation] Carvedilol improved stress cardiomyopathy through the activation of "telomere-p53-PGC signaling (2016)
  • Author(s): Motoi Okada
  • Organizer: AHA
  • Place of Presentation: NewOrleans, USA
  • Year and Date: 2016-11-14
  • Int'l Joint Research
• [Presentation] The potential association of previous β-blocker prescription and mortality in patients with sepsis (2016)
  • Author(s): Yuta Kashiwagi
  • Organizer: ESICM
  • Place of Presentation: Milan, Italy
  • Year and Date: 2016-10-03
  • Int'l Joint Research
• [Presentation] Carvedilol improves prognosis in sepsis-induced cardiomyopathy through the attenuation of telomere shortening (2016)
  • Author(s): Ｍｏｔｏｉ Ｏｋａｄａ
  • Organizer: ESC
  • Place of Presentation: Rome, Italy
  • Year and Date: 2016-08-28
  • Int'l Joint Research
• [Presentation] Carvedilol improves prognosis in sepsis-induced cardiomyopathy through the attenuation of telomere shortening (2016)
  • Author(s): Motoi Okada
  • Organizer: ESC ヨーロッパ心臓病学会
  • Place of Presentation: イタリア ローマ
  • Year and Date: 2016-08-28
  • Int'l Joint Research
• [Presentation] Previous prescription of β-blockers reduced mortality among patients for sepsis (2016)
  • Author(s): Motoi Okada
  • Organizer: KSCCM 韓国集中治療学会 日韓合同カンファランス
  • Place of Presentation: 韓国 ソウル
  • Year and Date: 2016-04-23
  • Int'l Joint Research
• [Book] 心不全 (2018)
  • Author(s): 岡田 基
  • Total Pages: 370
  • Publisher: 中山書店
  • ISBN: 9784521745831
• [Funded Workshop] ESC (2017)
• [Funded Workshop] ESC (2016)
  • Place of Presentation: Rome
  • Year and Date: 2016-08-27